New Two-Pronged antibody trial targets Tough-to-Treat blood cancer
Disease control
Not yet recruiting
This early-stage study is testing a new drug called EMB-07, combined with other treatments, for aggressive B-cell non-Hodgkin lymphoma. It will enroll about 115 adults, including those with newly diagnosed disease and those whose cancer has returned or resisted previous treatment…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai EpimAb Biotherapeutics Co., Ltd. • Aim: Disease control
Last updated Mar 23, 2026 15:14 UTC